Fresenius Medical Care multiFiltrate, Инструкция по эксплуатации

Страница: 200 / 282

Chapter 7: Functional description
7-12 Fresenius Medical Care multiFiltrate IFU-EN-UK 15A-2015
Frequently, an iso-oncotic human albumin solution is used. A lack of
coagulation factors or of other essential plasma components, whether
occurring as a result of the plasma exchange or otherwise, can be
counteracted by using fresh frozen plasma (FFP) as a replacement
solution, either completely or in part (in this case, preferably at the end
of the treatment).
In some cases, such as thrombotic thrombocytopenic purpura (TTP,
aka Moschcowitz syndrome), it is essential not only to remove the
pathologic plasma components, but also to reinfuse normal plasma
components with the replacement solution. Here, the use of FFP as the
replacement solution is recommended, or, alternatively, cryoprecipitate
plasma.
Efficacy During MPS, typically one to two times the patient's plasma volume is
exchanged.
Due to the decrease in plasma concentration in the substances to be
removed in the course of the treatment, an MPS treatment ends as soon
as the prescribed plasma volume has been replaced. If medically
necessary, further MPS treatments will not be performed until the
following day at the earliest.
Treatment parameters
MPS Min. Max. Resolution Unit
Blood flow 10 300 10 ml/min
Plasma Off / 10 10 1 ml/min
Temperature Off / 35 37 0.5 °C
Cont. heparin adm. Off / 0.1 25 0.1 ml/h